Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $8.00 at Canaccord Genuity Group

Taysha Gene Therapies (NASDAQ:TSHA) had its price target increased by equities researchers at Canaccord Genuity Group from $6.00 to $8.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target points to a potential upside of 258.74% from the stock’s current price.

Several other equities research analysts have also weighed in on TSHA. Chardan Capital restated a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Price Performance

TSHA stock opened at $2.23 on Friday. Taysha Gene Therapies has a one year low of $1.19 and a one year high of $4.32. The firm has a 50-day moving average of $1.98 and a two-hundred day moving average of $2.39. The firm has a market capitalization of $457.02 million, a PE ratio of 3.60 and a beta of 0.44. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.35.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 109.58%. The business had revenue of $1.11 million during the quarter, compared to the consensus estimate of $3.62 million. During the same quarter in the prior year, the firm earned ($0.38) EPS. On average, analysts forecast that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds have recently made changes to their positions in the company. Creative Planning acquired a new position in shares of Taysha Gene Therapies during the third quarter valued at $28,000. Principal Financial Group Inc. bought a new stake in Taysha Gene Therapies during the 2nd quarter worth about $48,000. China Universal Asset Management Co. Ltd. lifted its position in Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after purchasing an additional 17,446 shares during the period. Intech Investment Management LLC bought a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at about $85,000. Finally, Scientech Research LLC acquired a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $97,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.